Drug development company Algorae Pharmaceuticals (ASX: 1AI) has finalised an initial catalogue of 24 drug targets generated by Version 1.0 of its Algorae Operating System (AlgoraeOS) platform.
The platform was launched in October in collaboration with artificial intelligence (AI) experts at the University of New South Wales.
The 24 new drug targets have been reviewed for their commercial and intellectual property potential and will be taken to preclinical studies at an Australian pharmaceutical drug laboratory.
The targets are applicable to a range of oncology medical indications with significant unmet needs, including breast and lung cancer, leukaemia and glioblastoma.
In vitro preclinical assessments will verify efficacy and safety and serve to de-risk further development within the company or in partnership with other pharmaceutical firms.
“We are excited to reveal that we have successfully used the platform to expand our therapeutic pipeline by 24 promising new targets,” the company said.
“This significant expansion highlights the important competitive advantage of AI to predict new therapeutic entities ahead of our competitors relying on conventional approaches.”
“The targets which show promise in preclinical studies will be developed internally or earmarked for potential development with a partner.”
The cutting-edge AlgoraeOS platform uses complex algorithms and machine-learning models to predict fixed-dose combination drugs, which combine two or more active pharmaceutical ingredients into a single dosage form.
It aggregates medical and scientific data on over 5,000 known drugs and molecules across 150 human cell types.
The generated drug targets can be used to expand Algorae’s internal US Food and Drug Administration therapeutic pipeline or be licensed to third parties.
The platform is hosted by the ‘Gadi’ supercomputer operated by National Computational Infrastructure Australia and has been previously used for applications such as climate modelling and natural disaster prediction.
Algorae has commenced the development of Version 2.0 of AlgoraeOS to expand pharmaceutical databases, enhance AI models and increase predictive capacity in additional fields of medicine.
The company believes that the updated version will further improve prediction accuracy and expand the potential range of applications.
AlgoraeOS is currently the only platform of its kind in Australia.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。